Lung Cancer

Article	Citations
Risk-Based lung cancer screening: A systematic review	128
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe	100
Mechanisms of osimertinib resistance and emerging treatment options	87
Covid-19 and lung cancer: A greater fatality rate?	86
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world dat	85
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer	81
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors	72
Lung cancer prediction by Deep Learning to identify benign lung nodules	71
Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype	68
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer	67
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients	62
Vaping and lung cancer – A review of current data and recommendations	62
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study	62
Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer	60
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO	59
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC	53
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkp	53
Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis	51
Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy	51
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy	49
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)	48
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma	43
Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis	43
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)	42
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience	42

A cross-modal 3D deep learning for accurate lymph node metastasis prediction in clinical stage T1 lung adenocarcinoma	41
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer	41
Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma	41
Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial	41
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure	40
Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study	40
Cytology for PD-L1 testing: A systematic review	39
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer	38
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (Che	36
Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation	35
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)	35
Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis	34
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)	34
ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI	34
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases	33
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer	32
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer	32
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation	32
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients	31
A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients	31
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies	31
Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection	31
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection	31
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis	30
Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors	30
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)	30
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer	29
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMS	29
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis	29
Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 – Systematic review and meta-analysis	29
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer	29
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network	29
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations	29
Analysis of the baseline performance of five UK lung cancer screening programmes	28
A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease	28
Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrosp	28
Positive EGFR mutation status is a risk of recurrence in pN0–1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis	28
A systematic review of survival following anti-cancer treatment for small cell lung cancer	28
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study	27
Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy	27
Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on TCGA and GEO databases	27
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy	27
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients	26
Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors	26
Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment	26
Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma	26
Strategies to overcome resistance to immune checkpoint blockade in lung cancer	25
Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs)	25
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)	25
Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect	25

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?	25
Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study	25
Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation	25
Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716	24
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients	24
Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer	24
Lung cancer patients with COVID-19 in Spain: GRAVID study	24
Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data	24
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase	23
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma	23
Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models	23
Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations	23
Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib	23
NTRK fusions in lung cancer: From biology to therapy	23
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer	23
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer	23
Advanced bronchoscopic techniques for the diagnosis and treatment of peripheral lung cancer	23
Whole-exome and RNA sequencing of pulmonary carcinoid reveals chromosomal rearrangements associated with recurrence	23
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study	22
The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) p	22
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy	22
Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm	22
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience	21
Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer	21
Severe symptoms persist for Up to one year after diagnosis of stage I-III lung cancer: An analysis of province-wide patient reported outcomes	21
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement	21
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy	21
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling	21
NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration	21
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC	21
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers	21
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib	20
Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort	20
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab i	20
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis	20
A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer	20
Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges	20
Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer	20
Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer	20
NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer	20
Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease	20
Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report	19
Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature	19
Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment	19
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer	19
Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome	19
Breath profile as composite biomarkers for lung cancer diagnosis	19
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)	19
Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak	19
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing	19
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer	19
HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition	19
Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms	18
Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer	18
Prognostic significance of tumor spread through air spaces in patients with stage IA part-solid lung adenocarcinoma after sublobar resection	18
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226	18
The role of spread through air spaces (STAS) in lung adenocarcinoma prognosis and therapeutic decision making	18
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment	18
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyro	18
Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis	18
Socioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration	18
Cumulative pemetrexed dose increases the risk of nephrotoxicity	18
Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors	18
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers	17
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors	17
Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?	17
Preoperative CT-based peritumoral and tumoral radiomic features prediction for tumor spread through air spaces in clinical stage I lung adenocarcinoma	17
International real-world study of DLL3 expression in patients with small cell lung cancer	17
A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer	17
Integrative analyses identified ion channel genes GJB2 and SCNN1B as prognostic biomarkers and therapeutic targets for lung adenocarcinoma	17
Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy	17
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions	17
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients	17
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial	17
Infectious complications of EBUS-TBNA: A nested case-control study using 10-year registry data	17
The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients	17
KEAP1/NRF2 (NFE2L2) mutations in NSCLC – Fuel for a superresistant phenotype?	17
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial	17
The evolving role of liquid biopsy in lung cancer	17
Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemor	17

Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression	17
Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients	16
Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms	16
Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment	16
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis	16
Cost-effectiveness evaluation of robotic-assisted thoracoscopic surgery versus open thoracotomy and video-assisted thoracoscopic surgery for operable non-small cell lung cancer	16
Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors – The Ontario experience	16
Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer	16
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population	16
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis	16
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials	16
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial	16
STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)	16
Surgery for small cell lung cancer: When and how	16
Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “c	16
Occult lymph node metastases in clinical N0/N1 NSCLC; A single center in-depth analysis	16
The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands	16
Histopathological subtyping is a prognostic factor in stage IV lung adenocarcinoma	16
Clinical outcomes and the role of bronchoscopic intervention in patients with primary pulmonary salivary gland-type tumors	16
Role of dietary carbohydrates on risk of lung cancer	16
Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study	16
Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prosp	15
Perioperative targeted therapy for oncogene-driven NSCLC	15
Survival comparison of Three histological subtypes of lung squamous cell carcinoma: A population-based propensity score matching analysis	15
Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial	15
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction	15
The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance	15
Tumor-associated macrophage infiltration is associated with a higher rate of tumor spread through air spaces in resected lung adenocarcinomas	15
Targeting un-MET needs in advanced non-small cell lung cancer	15
Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study	15
Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported?	15
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study	15
Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer	15
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer	15
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy	15
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study	15
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases	15
Nationwide effect of high procedure volume in lung cancer surgery on in-house mortality in Germany	14
Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach	14
Extensive functional evaluation of exon 20 insertion mutations of EGFR	14
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)	14
Sarcopenia as independent risk factor of postpneumonectomy respiratory failure, ARDS and mortality	14
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab	14
Development and validation of a clinically applicable deep learning strategy (HONORS) for pulmonary nodule classification at CT: A retrospective multicentre study	14
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer	14
Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer	14
Outstanding negative prediction performance of solid pulmonary nodule volume AI for ultra-LDCT baseline lung cancer screening risk stratification	14
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer	14
Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma	14
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy	14
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab	14
Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial	14
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable,	14
Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer1	14
Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ	14
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer	14
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors	14
Is it necessary to sample the contralateral nodal stations by EBUS-TBNA in patients with lung cancer and clinical N0 / N1 on PET-CT?	13
Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis	13
Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis	13
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada	13
Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy	13
Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment	13
Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors	13
Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients	13
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy	13
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells	13
Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing	13
A risk prediction model for selecting high-risk population for computed tomography lung cancer screening in China	13
MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy	13
ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases	13
Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors	13
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study	13
Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand	13
The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment	13
Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients	13
Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer	13
Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer	13
Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors	13
Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre	13
Cribriform growth pattern in lung adenocarcinoma: More aggressive and poorer prognosis than acinar growth pattern	13
Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer	13
Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer	13
Quality of life after VATS lung resection and SABR for early-stage non-small cell lung cancer: A longitudinal study	12
Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study	12
Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort	12
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study	12
Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients	12
A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non–small cell lung cancer	12
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study	12
Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma	12
Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression	12
MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data	12
Real-world evidence for immunotherapy in the first line setting in small cell lung cancer	12
The Pandora’s box of novel technologies that may revolutionize lung cancer	12